



Symdeko[®] (tezacaftor/ivacaftor and ivacaftor) – Expanded indication

- On June 21, 2019, the [FDA announced](#) the approval of [Vertex's Symdeko \(tezacaftor/ivacaftor and ivacaftor\)](#), for the treatment of patients with cystic fibrosis (CF) age 6 years and older who are homozygous for the *F508del* mutation or who have at least one mutation in the cystic fibrosis transmembrane conductance regulator (*CFTR*) gene that is responsive to tezacaftor/ivacaftor based on *in vitro* data and/or clinical evidence.
 - Symdeko was previously approved in patients ages 12 and older who had the same specific genetic mutations.
 - If the patient's genotype is unknown, an FDA-cleared CF mutation test should be used to detect the presence of a *CFTR* mutation followed by verification with bi-directional sequencing when recommended by the mutation test instructions for use.
- The efficacy of Symdeko in patients age 6 to less than 12 years was extrapolated from patients age 12 years and older with support from population pharmacokinetic analyses showing similar tezacaftor and ivacaftor exposure levels in patients age 6 to less than 12 years and in patients age 12 years and older.
- The safety of Symdeko to treat cystic fibrosis patients age 6 to less than 12 years was supported by data from a study that included a 24-week, open-label treatment period with 70 cystic fibrosis patients age 6 to less than 12, and had similar observations of safety to clinical trials in age 12 and older.
- In addition to the expanded indication, the FDA also approved a new co-packaged formulation for Symdeko containing tezacaftor 50 mg/ivacaftor 75 mg fixed-dose combination tablets and ivacaftor 75 mg tablets.
 - Symdeko was previously only available as a co-packaged product containing tezacaftor 100 mg/ivacaftor 150 mg fixed-dose combination tablets and ivacaftor 150 mg tablets.
- The recommended dose for Symdeko in pediatric patients age 6 to less than 12 years weighing less than 30 kg is one tablet (containing tezacaftor 50 mg/ivacaftor 75 mg) in the morning and one tablet (containing ivacaftor 75 mg) in the evening.
- The recommended dose of Symdeko in adults and pediatric patients age 12 years and older or pediatric patients age 6 to less than 12 years weighing 30 kg or more is one tablet (containing tezacaftor 100 mg/ivacaftor 150 mg) in the morning and one tablet (containing ivacaftor 150 mg) in the evening.
- Vertex's launch plans for the new Symdeko co-packaged product are pending.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.